Tuesday, June 29, 2021 2:00:35 PM
Dr. Williams will be speaking at the scientific conference at 11:30am ET on June 29, 2021.
The topic is “Personalized, off-the-shelf cellular immunotherapy for cancer”.
A copy of the presentation will be posted here: https://briacell.com/novel-technology/scientific-publications/.
For additional information on the conference and the speaker, please visit:
https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers
Separately, BriaCell has recently appointed Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC). Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis. More recently, Dr. Lopez-Lago has been interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies. Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
For additional information on BriaCell, please visit: https://briacell.com/.
Recent BCTX News
- BriaCell Announces Oral and Poster Presentations at ASCO 2024 • GlobeNewswire Inc. • 04/24/2024 12:00:33 PM
- BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies • GlobeNewswire Inc. • 03/07/2024 01:00:00 PM
- BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference • GlobeNewswire Inc. • 03/06/2024 01:00:26 PM
- BriaCell Provides Update on Alleged Illegal Trading of Public Securities • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case • GlobeNewswire Inc. • 02/07/2024 01:00:37 PM
- Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing • GlobeNewswire Inc. • 02/06/2024 01:30:53 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 10:24:58 PM
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting • GlobeNewswire Inc. • 01/31/2024 03:48:36 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/22/2024 10:00:49 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/09/2024 09:05:36 PM
- BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer • GlobeNewswire Inc. • 01/04/2024 01:45:00 PM
- BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients • GlobeNewswire Inc. • 12/28/2023 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:38 PM
- BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset • GlobeNewswire Inc. • 12/20/2023 01:40:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/14/2023 10:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 10:00:35 PM
- BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS • GlobeNewswire Inc. • 12/06/2023 02:31:11 PM
- BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit • GlobeNewswire Inc. • 12/06/2023 02:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/30/2023 12:00:38 PM
- BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor • GlobeNewswire Inc. • 11/30/2023 12:00:00 PM
- BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND • GlobeNewswire Inc. • 11/03/2023 12:31:01 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM